FIREFLY-1 Trial to Test Oral Pan-RAF Inhibitor in Low-Grade Glioma
In a phase 2 study, researchers are evaluating DAY101 in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma.
Day One Biopharmaceuticals Inc Oncology Consortium Multicenter Study Pediatric Patients With Progressive Low Grade Pacific Pediatric Neuro Oncology
Source: cancertherapyadvisor.com